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Abstract 
 
Introduction. Tourette syndrome is a neurodevelopmental disorder characterized by multiple 
motor tics and at least one vocal/phonic tic. Clinical phenotypes show a wide variability, 
often incorporating behavioral symptoms. The exact pathophysiology of Tourette syndrome 
is unknown, however genetic vulnerability and alterations in dopaminergic neurotransmission 
have consistently been reported. Other biochemical pathways, including histaminergic 
neurotransmission, are likely to be involved but have received relatively little attention until 
recently. 
Areas covered. We conducted a systematic literature review focusing on the role of 
histaminergic neurotransmission and its pharmacological modulation in Tourette syndrome. 
We identified a number of relevant original studies published over the last five years, mainly 
focusing on genetic aspects.  
Expert opinion. There is converging evidence from recent studies supporting the hypothesis 
that histaminergic neurotransmission may play a role in the pathophysiology of Tourette 
syndrome. Most studies focused on the role of the histidine decarboxylase gene and the 
potential usefulness of histidine decarboxylase knockout mice as an experimental model for 
studying neurochemical function in Tourette syndrome. There have been no large scale 
studies assessing the use of histaminergic medications in the management of Tourette 
syndrome. This would be an important area for future research, with direct implications for 
the clinical management of selected phenotypes. 
 
Keywords: histamine, Tourette syndrome, tics, animal models, treatment 
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1. Introduction 
1.1. Tourette Syndrome 
Tourette syndrome (TS), first described in the medical literature by French neurologist 
Georges Gilles de la Tourette in the second half of the XIX Century, is a neurodevelopmental 
disorder characterized by chronic motor and vocal tics [1-4]. Tics are defined as sudden, 
repetitive, non-rhythmic, involuntary movements and vocalizations [5]. The most common 
motor tics include eye blinking, facial grimacing, neck stretching, and shoulder shrugging, 
whereas vocal tics - more appropriately referred to as phonic tics as vocal chords are not 
always involved - are mainly represented by grunting, sniffing, and throat clearing [6]. 
Interestingly, tics are characteristically preceded by subjective urges which are relieved by tic 
expression and can be resisted only for a limited length of time, at the expense of mounting 
inner tension [7-12]. According to the DSM-5, diagnostic criteria for TS focus on the 
presence of multiple motor tics plus at least one vocal tic, with onset before the age of 18 
years and lasting for over a year [13]. Based on epidemiological studies mainly carried out in 
school-age children, TS is thought to affect between 0.3% and 0.9% of the population, with a 
male-to-female ratio of 3-4:1 [6,14,15]. Onset is typically in early childhood; one large 
multicenter study reported a mean age of onset of 6.4 years [16]. A considerable proportion 
of patients experience a decline in both the frequency and severity of their symptoms as they 
enter adult life [17]. Around 90% of patients with TS are diagnosed with co-morbid 
psychiatric disorders [16,18,19]. The most common behavioral co-morbidities are obsessive-
compulsive disorder [20,21] and attention deficit and hyperactivity disorder [22,23], although 
affective disorders [24] and impulse control disorders [25-27] have been reported more 
commonly in patients with TS than in the general population.  
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The exact pathophysiological mechanisms underlying TS are unknown, however converging 
lines of evidence point to abnormally increased dopamine neurotransmission, particularly at 
the level of the basal ganglia and fronto-striatal circuitries [2,28-30]. This hypothesis is in 
line with evidence of altered structural connectivity within the cortico-striato-pallido-
thalamic circuitry [31]. As with other neurodevelopmental conditions, there is solid evidence 
for a genetic component to the expression of TS [32,33], thought to involve complex 
multigene changes [34]. TS has a heritability of approximately 0.58 [35] and its genetic 
heterogeneity has recently been confirmed by the results of recent large studies, which have 
failed to identify a single shared mutation or even common polymorphisms [36]. 
Environmental factors also play a role and autoimmune mechanisms have been proposed to 
be involved at least in a subgroup of patients [37,38]. 
A proportion of patients with TS do not require intervention, however when tics and/or co-
morbid behavioral problems are considered physically, socially or emotionally disabling and 
cause functional impairment, active treatment can be implemented [39]. Management of TS 
is primarily pharmacological [39,40], although behavioral therapies [41,42] and neurosurgical 
interventions [43-45] have shown benefit in selected patients. Pharmacological agents 
belonging to a number of classes are routinely used in the treatment of TS, the most 
commonly prescribed being dopamine antagonists [46]. First-line treatment options often 
include either an alpha-adrenergic agonist such as clonidine [47] or atypical antipsychotic 
agents such as risperidone and aripiprazole [39]. Second-line options include old generation 
or typical neuroleptics, such as haloperidol and pimozide, with established efficacy but worse 
tolerability profiles [48]. In a number of cases polypharmacy is needed, alongside behavioral 
interventions, such as habit reversal training [49,50], and, in refractory cases, deep brain 
stimulation [43-45]. 
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1.2. Dopaminergic and Histaminergic Pathways in Tourette Syndrome 
Although the majority of studies have supported the role of dopamine in TS, there is growing 
evidence for alterations across multiple biochemical systems [51,52], including abnormal 
histaminergic neurotransmission [53]. Histamine is an organic nitrogenous compound that 
acts as a signaling molecule in the immune and gastrointestinal systems, as well as a 
neurotransmitter within the central nervous system [54]. Histaminergic neurons mainly 
originate from the tuberomamillary nucleus of the hypothalamus [55], and their widespread 
projections reach most areas of the brain. Histamine acts through four receptors (H1-H4) and 
actively regulates arousal, feeding, learning and memory processes [56,57]. H1 and H2 
receptors are expressed throughout the central nervous system, H3 receptors are limited to the 
brain, and H4 receptors are primarily located in the immune system, with limited action on 
the brain [58,59]. Specifically, H3 receptors are found in high concentrations throughout the 
cortex, hippocampus and striatum [54], the latter of which has been strongly associated with 
TS pathophysiology. Moreover, H3 receptors in the striatum have been shown to have 
significant roles in modulating dopaminergic neurotransmission [59,60], thus further 
supporting their possible role in TS [61]. Specifically, histamine neurotransmission appears 
to reduce the concentration of dopamine in the striatum by acting at H3 heteroreceptors on 
dopaminergic afferents. Through this action, histamine can exert control on the dopaminergic 
pathways targeting the GABAergic medium-spiny projection neurons that make up 
approximately 95% of all striatal neurons,  thereby affecting the behaviour of the basal 
ganglia as a whole. 
 
1.3. Histaminergic Neurotransmission and Neuropsychiatric Disorders 
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Alterations in histaminergic pathways are known to have far-reaching consequences and it is 
therefore not surprising that histamine neurotransmission has been implicated in a number of 
neurological conditions [62-66]. For example, in post-mortem studies of patients with 
Alzheimer disease, levels of histamine were reduced in the hypothalamus, hippocampus and 
temporal lobes when compared to controls [67]. Histamine has also been shown to decrease 
neurotoxicity produced by β-amyloid in Alzheimer disease, a process that appears to be 
regulated by the H2 and H3 receptor subtypes. Overall, H3 receptors have also been 
implicated in suppressing histamine release in the brain. Therefore, pharmacological agents 
known to antagonize the H3 receptor and to regulate the H2 receptor have been proposed as 
promising treatment avenues for patients with Alzheimer disease [68]. Likewise, reduced 
histamine levels have also been demonstrated after bilateral carotid artery occlusion in rats, 
suggesting a potential role in vascular dementia [69]. Furthermore, patients with Parkinson 
disease, but not those with more severe forms of ‘Parkinson-plus’ conditions such as multiple 
system atrophy, were found to have increased levels of brain histamine [70]. Finally, low 
histamine levels have been documented in patients with epilepsy and H3 receptor blockade 
(which increases endogenous brain histamine release) has been reported to increase seizure 
threshold [71]. Studies investigating the role of other histamine receptors have produced 
mixed results [72]. 
 
1.4. Systematic Literature Review 
This article will systematically review the current evidence for the role of histaminergic 
neurotransmission in TS. In order to comprehensively identify relevant articles within this 
dynamic research area, the PRISMA guidelines for reporting systematic literature reviews 
[73] were followed. Both PubMed and PsycInfo databases were searched using the search 
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terms tourett* OR tic* AND histamin* and limited to English language. After removing 
duplicates and studies not focusing on histamine and/or TS, the authors manually screened 
the abstracts of the remaining articles for relevance to histaminergic neurotransmission in TS, 
and identified the studies that are included in this review. 
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2. Tourette Syndrome and Histaminergic Neurotransmission 
2.1. Clinical Studies 
A small number of original studies have been carried out to specifically investigate the role of 
histamine neurotransmission in TS. A genetic linkage study carried out on a family with an 
unusually high prevalence of TS provided initial evidence of a possible role of histaminergic 
dysfunction [74]. DNA samples from all family members in the two-generation pedigree 
were obtained and genotyped. The father and all eight offspring met the DSM-IV-TR 
diagnostic criteria for TS [75], whereas the mother and extended family were apparently free 
from tics or other symptoms of TS. In terms of TS-related behavioral symptoms, the father 
and two children also had obsessive-compulsive disorder. This family showed a Mendelian 
pattern of autosomal dominant inheritance, which is rarely seen in TS. Polymerase chain 
reaction (PCR) analyses identified a premature termination codon (W317X) on exon 9 of the 
histidine decarboxylase (HDC) gene, which was present in the father and offspring, but 
absent in the mother. This termination codon resulted from a guanine-to-adenosine transition 
at the nucleotide 951 position of the gene, leading to a complete loss of enzyme function. The 
HDC gene codes for the enzyme histidine decarboxylase, a rate-limiting enzyme in the 
biosynthesis of histamine from L-histidine [53]. These findings therefore suggested a 
potential role for HDC deficiency in the pathophysiology of TS through impairment of 
histamine neurotransmission. However, the inheritance pattern in this family is uncommon 
for TS, and a mutation screening of Chinese Han patients did not support the link between the 
aforementioned gene and TS [76]. 
In 2012, a case-control study of 460 patients with TS focused on copy number variants 
(CNVs) to identify risk regions or molecular pathways which may be associated with TS 
[77].  The authors found no statistically significant increase in CNVs when comparing 
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patients with TS to controls, however there was some overlap between CNVs found in 
patients with TS and those previously identified in autism spectrum disorder. Moreover, 
pathway analysis showed enrichment of genes within the H1 and H2 receptor signaling 
pathways. Presynaptic receptors in these pathways regulate release of histamine and of other 
neurotransmitters such as dopamine, suggesting wider neural signaling abnormalities in TS. 
A limiting factor of this study was the relatively small sample size compared to similar CNV 
analyses in other patient cohorts.  
The identification of the previously mentioned HDC mutation led to a study in 2013 that 
investigated variations across the whole HDC gene [78]. This study involved 520 families 
with TS from seven European Countries. Genotyping studies found strong over-transmission 
of alleles at two single nucleotide polymorphisms (rs854150 and rs1894236). These results 
confirmed a putative role for histamine pathways in neuronal development, and provided 
further support to the hypothesis that dysfunction in these pathways may be involved in 
development of TS at least in a subgroup of patients. 
  
2.2. The HDC Knockout Mouse Model 
HDC deficiency was investigated in a recent study [79] using a HDC knockout model. 
Although mice which are deficient in the HDC gene do not exhibit detectable tic-like 
movements at baseline, when challenged with either high-dose psychostimulants or acute 
stress they develop repetitive purposeless movements (e.g. focused sniffing, orofacial 
movements, excessive grooming) that may resemble tic symptoms. Clearly no animal model 
can capture all aspects of the complex phenomenology of TS, however these behavioral 
phenotypes were thought to be qualitatively different to the increased locomotion upon 
stimulant administration and amphetamine-induced stereotypies observed in healthy mice. 
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Interestingly, these tic-like behaviors could be alleviated by repletion of histamine via 
intracerebral infusion. Furthermore, striatal dopamine levels appeared to be negatively 
regulated by histamine, as the HDC knockout mice exhibited increased dopamine turnover. In 
consideration of the known role of increased dopamine neurotransmission in the 
pathophysiology of TS, these results provided in vivo experimental evidence of a direct 
relationship between histamine and dopamine regulation in the basal ganglia. Interestingly, it 
was noted that the decrease or disappearance of tics in patients with TS parallels the circadian 
pattern of histamine. The histaminergic neurons projecting from the tuberomamillary nucleus 
of the hypothalamus to a wide range of brain structures, including the striatum, fire at high 
frequency during wakefulness and are virtually silent during sleep. The possibility that 
histamine exerts a diurnal control on the activity of the basal ganglia circuitry would be in 
line with the known fluctuations in tic expression (waxing and waning during day time and 
decrease/remission during night time). The authors of these experiments acknowledged the 
possibility that the HDC knockout mouse model might be representative of a relatively rare 
pathophysiological mechanism for TS and that this might therefore be relevant to only a 
small proportion of patients with TS. However, these findings led to the suggestion that 
increasing brain histamine could potentially be of therapeutic benefit, and that dietary 
supplementation with histidine may increase histamine production.  
The HDC knockout mouse model was also used in a further study from 2014 analyzing 
changes in signaling pathways in the striatal cells in comparison to animals [80]. The study 
found that levels of dopamine were higher in the HDC knockout mice, and there were also 
alterations to protein kinase B Akt and mitogen-activated protein kinase (MAPK) signaling 
pathways. The changes discovered in these pathways are characteristic of the effects of 
dopamine on striatal neurons. Furthermore, the investigators identified glycogen synthase 
kinase 3 beta (GSK3β) as a potential therapeutic target due to its role in the AKT pathway. 
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Since the first reports of a possible association between HDC deficiency and TS, the HDC 
knockout mice paradigm has been used in multiple studies as an experimental model of TS. 
This model opened promising avenues, as HDC knockout mice show a phenotype that shares 
some components with the symptoms of patients with TS [81]. Specifically, the study by 
Castellan Baldan et al. [79] provided evidence for disturbed sensorimotor gating in HDC 
knockout mice, as indicated by reduced pre-pulse inhibition (a neurophysiological 
phenomenon in which a weak pre-stimulus sound inhibits the reaction to a subsequent strong 
startling stimulus). Reduction in pre-pulse inhibition was also observed in patients with TS 
carrying the HDC W317X mutation [74], presumably as a result of elevation of striatal 
dopamine levels [82], which is in turn caused by a lack of inhibitory effect of histamine on 
dopamine release. This hypothesis was confirmed by the findings of the study by Castellan 
Baldan et al. [79], who directly determined striatal dopamine using micro-dialysis: during the 
night-phase, when mice become active, striatal levels of histamine were found to be increased 
in wild-type mice, but not in HDC knockout mice; conversely, dopamine levels were 
significantly higher during the night phase in HDC knockout mice as compared to wild-type 
controls [79]. The inhibitory effect of histamine was further demonstrated by histamine 
infusion into wild-type mice, resulting in a significant reduction in striatal dopamine 
compared to saline controls [79]. Finally, both patients with TS carrying the HDC W317X 
mutation and HDC knockout mice showed an upregulation of dopamine D2 and D3 receptors 
in the substantia nigra, as determined by positron emission tomography in the patients with 
TS using 11C-labeled 4-propyl-9-hydroxynaphthoxazine binding or by 3H-raclopride binding 
to brain slices of HDC knockout mice [79]. Taken together, these findings suggested that 
HDC knockout mice may represent a valid animal model for human TS, although the tic-like 
repetitive behaviors (e.g. sniffing-like head movements) observed in HDC knockout mice in 
the study by Castellan Baldan et al. [79] were not observed at baseline, but emerged after 
Invited article for Expert Opin Orphan Drugs 
 
14 
 
acute challenge with the psychostimulant amphetamine (and were completely eliminated by 
pretreatment with either haloperidol or histamine). The fact that amphetamine was necessary 
to induce a tic-like phenotype in HDC knockout mice brought further evidence to suggest that 
these animal models are only partly comparable to patients with TS, who display symptoms 
without pharmacological challenge. A recent study by Xu et al. [83] tested the ability of an 
acute stressor to stimulate repetitive behaviors in this experimental model using tone fear 
conditioning. HDC knockout mice acquired conditioned fear normally, as manifested by 
freezing during the presentation of a tone 48 hours after it had been paired with a shock. 
During the 30 minutes following tone presentation, knockout mice showed increased 
grooming, whereas heterozygote mice exhibited normal freezing and intermediate grooming. 
These data validated a new paradigm for the examination of tic-like repetitive behaviors in 
animals without pharmacological challenge and enhanced the face validity of HDC knockout 
mice as a pathophysiologically grounded model of tic disorders. 
 
2.3. Pharmacological Modulation 
At present, no large-scale clinical trials of histaminergic modulators have been undertaken in 
the TS patient population. A preliminary report from 1986 presented a small case series of 
three patients with TS where use of antihistaminergic agents exacerbated tics [84]. Caution is 
required when interpreting these findings, also in consideration of the non-selectivity 
(anticholinergic properties etc.) of antihistaminergic medications in clinical use. More 
recently, a case report published in 2012 presented the case of a male patient with TS and co-
morbid narcolepsy [85]. This patient’s condition had proven refractory to treatment with a 
number of antidopaminergic medications. Based on the findings of the study by Ercan-
Sencicek et al. [74], the patient underwent a trial with the H3 receptor inverse agonist 
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pitolisant. The authors found that pitolisant significantly decreased daytime sleepiness 
without worsening in tic severity, a common side effect associated with other 
psychostimulants such as methylphenidate and modafinil. However, contrary to what could 
be expected based on the histamine hypothesis of tics, the administration of pitolisant resulted 
in no significant improvement in tic severity. The authors considered that the lack of tic 
worsening in a sensitive patient (who had experienced worsening of tics on both 
methylphenidate and modafinil) warranted a controlled clinical trial of H3 receptor reverse 
agonists in patients with TS, particularly in the presence of co-morbid attention deficit 
hyperactivity disorder. It should be noted however that stimulant medications are not 
consistently associated with tic exacerbations, especially if administered in lower doses and 
with gradual titration [86,87]. Further supported by results of a positron emission tomography 
study assessing the novel H3 receptor antagonist AZD5213 [88], a randomized-controlled 
trial assessing its use has been undertaken, but as yet no results have been published 
(ClinicalTrials.gov: NCT01904773). 
There is evidence that histamine can directly control striatal neurons by affecting the activity 
of multiple neurotransmitters which are supposed to play a role alongside dopamine in the 
pathophysiology of TS [51-53]. Histamine can modulate the intrinsic electrical properties of 
striatal cholinergic interneurons and negatively regulate the release of GABA from striatal 
medium-spiny projection neurons by acting at the level of H3 heteroreceptors. Through the 
same mechanism, histamine can also modulate glutamatergic neurotransmission by 
decreasing the release of glutamate from striatal synaptosomes and reducing the electrically 
evoked glutamatergic field responses. Finally, it is possible that the histaminergic action 
affects other striatal neuromodulatory pathways, such as the noradrenergic and serotoninergic 
pathways, which would allow for complex interactions amongst neuromodulators, thus 
expanding the spectrum of potential pharmacological targets for TS. 
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3. Expert Opinion 
3.1. Promising Avenues for Research 
Our systematic literature review was able to identify a small number of original studies 
specifically investigating histaminergic neurotransmission in TS. Interest in this topic was 
first generated by the report that a rare mutation in the HDC gene (W317X) was associated 
with the occurrence of TS in a two-generation pedigree [74]. Patients with the W317X 
mutation of HDC are unable to synthesize histamine and depend on the activity of HDC 
encoded by the non-mutated second allele. The presence of specific psychiatric co-
morbidities in some male members of this pedigree could also be explained by a dysfunction 
in the histaminergic system, as overriding inhibition of competing pathways within parallel 
cortico-striato-thalamo-cortical loops can hinder behavioral switching as seen in obsessive-
compulsive disorder [89]. A more general association of histaminergic pathways with TS was 
identified by analysis of rare CNVs in a subsequent study [77]. The hypothesis of an 
involvement of the histaminergic system in the pathogenesis of TS was also supported by a 
more recent report on single nucleotide polymorphisms in the HDC region that are associated 
with TS [78]. However, HDC mutations were not replicated in larger scale studies [76], 
suggesting that these genetic alterations may only be responsible for a subset of patients with 
TS. Interestingly, we have recently seen increasing consensus that TS is a heterogeneous 
condition from both the phenotypic and genotypic points of view. Studies conducted using 
principal-component factor analysis [90-95], hierarchical cluster analysis [90,93,94,96] and 
latent class analysis [97,98] have identified a number of clinical phenotypes which, if 
replicated, could prompt further research into individual genotype correlates. Perhaps the 
main limitation in our understanding of the role of histaminergic neurotransmission for the 
pathophysiology of TS is its limited generalizability, since a significant proportion of patients 
with TS have not shown any alterations in the HDC gene, indicating that this might be a rare 
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pattern of TS inheritance. Further exploration of the role of histaminergic transmission in TS 
might still offer some insight if associated with careful stratification of patients by specific 
behavioral and intermediate phenotypes within the TS spectrum. Based on the reviewed 
evidence, these points should stand as key lessons for the industry. In order to increase the 
knowledge base in this area, further research into other areas of histaminergic 
neurotransmission should be conducted. Examples may include comparing brain histamine 
levels in large cohorts of patients with TS and healthy controls, or carrying out further gene 
identification studies. Functional molecular neuroimaging studies may also provide a 
promising avenue of research. 
If alterations in histaminergic neurotransmission are identified in a large cohort of patients 
with TS, this might have a significant payback in the design of novel classes of medications 
that modulate histamine and carry direct therapeutic implications. Based on current evidence, 
patients with TS associated with HDC deficiency may benefit from pharmacological 
histamine modulation, particularly involving agents acting on the H3 receptor. Expression of 
H3 receptors has been reported to be elevated in the HDC knockout model of TS at the level 
of the basal ganglia [99], a key region for the pathophysiology of TS, as altered striatal 
histaminergic-dopaminergic tone has been shown to potentially result in tic generation [89]. 
H3 receptors are thought to be localized primarily presynaptically, both as autoreceptors on 
histaminergic terminals, where they may play a role in negative feedback regulation of 
histamine release, and as a heteroreceptors on dopaminergic, glutamatergic and cholinergic 
neurons. Moreover the expression of this receptor is largely specific to the central nervous 
system, indicating that it could be pharmacologically targeted with minimal concern about 
peripheral side effects. Although pilot clinical studies in narcolepsy, schizophrenia and 
attention deficit disorder have yielded mixed results (with more favorable outcomes in 
conditions characterized by hypersomnia), preclinical evidence strongly suggests that H3 
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antagonism could open novel therapeutic avenues in TS and other neuropsychiatric disorders 
[99]. Specifically, the use of H3 antagonists could be assessed either as a monotherapy or in 
combination therapy for patients already taking medication, with the goal of expanding the 
relatively narrow range of safe and effective pharmacological options currently available to 
clinicians treating patients with TS [39,40,100]. Further implications of additional research 
into this field may include identification of families at risk of TS. Although TS is not known 
to shorten life expectancy, it can be highly detrimental to patients’ health-related quality of 
life and psychosocial wellbeing [101-103]. Finally, recent observations that patients with TS 
can be prone to develop allergy related to histamine-associated immunological reactions 
prompt further investigations into the relationship between allergy, histamine and TS [104]. 
 
3.2 Preliminary Conclusions 
In conclusion, although the results of a number of small scale studies support the hypothesis 
that histaminergic neurotransmission may play a role in the pathophysiology of TS, the 
majority of research has focused on the role of the HDC gene and there have been no large 
scale studies assessing the use of histaminergic medications in the management of TS. The 
wide phenotypic heterogeneity that characterizes TS poses as a significant challenge; 
however recent research has paved the way for further work into the identification of more 
precise genotype-phenotype correlations. Histaminergic neurotransmission is an area of 
interest for future research, with potential to impact the management and treatment of patients 
in the long term. 
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Article Highlights 
 
- Tourette syndrome is a chronic tic disorder traditionally associated with alterations of 
dopaminergic neurotransmission, although the exact pathophysiology is still unknown. 
 
- Other biochemical pathways, involving histaminergic neurotransmission, are likely to play a 
role in Tourette syndrome pathophysiology, but have received relatively little attention until 
recently. 
 
- We identified a number of relevant original studies exploring the possible role of 
histaminergic transmission in Tourette syndrome, published over the last five years. 
 
- Most studies focused on the role of the histidine decarboxylase gene and the potential 
usefulness of histidine decarboxylase knockout mice as an experimental model for studying 
neurochemical function in Tourette syndrome. 
 
- Development and large-scale use of histaminergic medications deserve further research, 
with direct implications for the clinical management of selected Tourette syndrome 
phenotypes. 
 
